{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:33:23Z","timestamp":1778070803534,"version":"3.51.4"},"reference-count":27,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["dir"],"DOI":"10.4274\/dir.2025.253590","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:47:19Z","timestamp":1762177639000},"source":"Crossref","is-referenced-by-count":3,"title":["Diagnostic performance of magnetic resonance imaging-targeted biopsy for PI-RADS \u22653 peripheral zone lesions in multiparametric prostate magnetic resonance imaging: correlation with clinically significant prostate cancer"],"prefix":"10.4274","author":[{"given":"Serdar","family":"Aslan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emrah","family":"S\u00fcl\u00fcn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ertu\u011frul","family":"\u00c7ak\u0131r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ural","family":"O\u011fuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T\u00fcmay","family":"Bek\u00e7i","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. [Crossref]","DOI":"10.3322\/caac.21820"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Yacoub JH, Oto A. MR imaging of prostate zonal anatomy. Radiol Clin North Am. 2018;56(2):197-209. [Crossref]","DOI":"10.1016\/j.rcl.2017.10.003"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Lee CH, Akin-Olugbade O, Kirschenbaum A. Overview of prostate anatomy, histology, and pathology. Endocrinol Metab Clin North Am. 2011;40(3):565-575, viii-ix. [Crossref]","DOI":"10.1016\/j.ecl.2011.05.012"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Madersbacher S, Alcaraz A, Emberton M, et al. The influence of family history on prostate cancer risk: implications for clinical management. BJU Int. 2011;107(5):716-721. [Crossref]","DOI":"10.1111\/j.1464-410X.2010.10024.x"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng\/mL: systematic review and meta-analysis. Eur Urol. 2005;48(3):386-99; discussion 398-399. [Crossref]","DOI":"10.1016\/j.eururo.2005.04.015"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Huang Y, Li ZZ, Huang YL, Song HJ, Wang YJ. Value of free\/total prostate-specific antigen (f\/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10\u200a ng\/mL: a meta-analysis. Medicine (Baltimore). 2018;97(13):e0249. [Crossref]","DOI":"10.1097\/MD.0000000000010249"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992;147(3 Pt 2):815-816. [Crossref]","DOI":"10.1016\/S0022-5347(17)37393-7"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Omer A, Lamb AD. Optimizing prostate biopsy techniques. Curr Opin Urol. 2019;29(6):578-586. [Crossref]","DOI":"10.1097\/MOU.0000000000000678"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol. 2015;68(3):438-450. [Crossref]","DOI":"10.1016\/j.eururo.2014.11.037"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Brown AM, Elbuluk O, Mertan F, et al. Recent advances in image-guided targeted prostate biopsy. Abdom Imaging. 2015;40(6):1788-1799. [Crossref]","DOI":"10.1007\/s00261-015-0353-8"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Gaziev G, Wadhwa K, Barrett T, et al. Defining the learning curve for multiparametric magnetic resonance imaging (MRI) of the prostate using MRI-transrectal ultrasonography (TRUS) fusion-guided transperineal prostate biopsies as a validation tool. BJU Int. 2016;117(1):80-86. [Crossref]","DOI":"10.1111\/bju.12892"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol. 2019;76(3):340-351. [Crossref]","DOI":"10.1016\/j.eururo.2019.02.033"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024;86(2):148-163. [Crossref]","DOI":"10.1016\/j.eururo.2024.03.027"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Ahdoot M, Wilbur AR, Reese SE, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med. 2020;382(10):917-928. [Crossref]","DOI":"10.1056\/NEJMoa1910038"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244-252. [Crossref]","DOI":"10.1097\/PAS.0000000000000530"},{"key":"ref15","unstructured":"16. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767-1777. [Crossref]"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. G\u00f6rtz M, Radtke JP, Hatiboglu G, et al. The value of prostate-specific antigen density for prostate imaging-reporting and data system 3 lesions on multiparametric magnetic resonance imaging: a strategy to avoid unnecessary prostate biopsies. Eur Urol Focus. 2021;7(2):325-331. [Crossref]","DOI":"10.1016\/j.euf.2019.11.012"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Brizmohun Appayya M, Sidhu HS, Dikaios N, et al. Characterizing indeterminate (Likert-score 3\/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI. Br J Radiol. 2018;91(1083):20170645. [Crossref]","DOI":"10.1259\/bjr.20170645"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. In de Braekt T, van Rooij SBT, Daniels-Gooszen AW, et al. Accuracy of MRI-ultrasound fusion-guided and systematic biopsy of the prostate. Br J Radiol. 2024;97(1158):1132-1138. [Crossref]","DOI":"10.1093\/bjr\/tqae080"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Ullrich T, Arsov C, Quentin M, et al. Analysis of PI-RADS 4 cases: management recommendations for negatively biopsied patients. Eur J Radiol. 2019;113:1-6. [Crossref]","DOI":"10.1016\/j.ejrad.2019.01.030"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Liu Y, Wang S, Xu G, et al. Effectiveness and accuracy of MRI-ultrasound fusion targeted biopsy based on PI-RADS v2.1 category in transition\/peripheral zone of the prostate. J Magn Reson Imaging. 2023;58(3):709-717. [Crossref]","DOI":"10.1002\/jmri.28614"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Nativ O, Shefler A, Bejar J, et al. Performance of standard systematic biopsy versus MRI\/TRUS fusion biopsy using the Navigo\u00ae system in contemporary cohort. Urol Oncol. 2024;42(5):159.e1-159.e7. [Crossref]","DOI":"10.1016\/j.urolonc.2024.01.026"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Pepe P, Pepe L, Fiorentino V, Curduman M, Fraggetta F. Multiparametric MRI targeted prostate biopsy: when omit systematic biopsy? Arch Ital Urol Androl. 2024;96(4):12992. [Crossref]","DOI":"10.4081\/aiua.2024.12992"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Distler FA, Radtke JP, Bonekamp D, et al. The value of PSA density in combination with PI-RADS\u2122 for the accuracy of prostate cancer prediction. J Urol. 2017;198(3):575-582. [Crossref]","DOI":"10.1016\/j.juro.2017.03.130"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Zhou CK, Check DP, Lortet-Tieulent J, et al. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer. 2016;138(6):1388-400. [Crossref]","DOI":"10.1002\/ijc.29894"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Fiorentino V, Pepe L, Zuccal\u00e0 V, et al. Gleason score down and upgrading at radical prostatectomy in targeted vs. systematic prostate biopsy: findings from an institutional cohort. Pathol Res Pract. 2025;271:156040. [Crossref]","DOI":"10.1016\/j.prp.2025.156040"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Greer MD, Brown AM, Shih JH, et al. Accuracy and agreement of PIRADSv2 for prostate cancer mpMRI: a multireader study. J Magn Reson Imaging. 2017;45(2):579-585. [Crossref]","DOI":"10.1002\/jmri.25372"}],"container-title":["Diagnostic and Interventional Radiology"],"original-title":[],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:47:01Z","timestamp":1777895221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dirjournal.org\/articles\/diagnostic-performance-of-magnetic-resonance-imaging-targeted-biopsy-for-pi-rads-3-peripheral-zone-lesions-in-multiparametric-prostate-magnetic-resonance-imaging-correlation-with-clinically-significant-prostate-cancer\/doi\/dir.2025.253590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":27,"URL":"https:\/\/doi.org\/10.4274\/dir.2025.253590","relation":{},"ISSN":["1305-3825","1305-3612"],"issn-type":[{"value":"1305-3825","type":"print"},{"value":"1305-3612","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]}}}